Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19038307 | 0.85 | MAN1B1 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL25102515 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL22291233 | 0.78 | — | — | |
| SCHEMBL31275558 | 0.72 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL31275456 | 0.72 | CHRM2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17404751 | 0.67 | — | — | |
| SCHEMBL22856593 | 0.67 | SLC6A2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL753612 | 0.67 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17491806 | 0.67 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17491804 | 0.67 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964224-B1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2024-07-03 | — | — | EP | disclosed |
| US-20170216308-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2017-08-03 | — | — | US | disclosed |
| US-20170216308-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2017-08-03 | — | — | US | disclosed |
| US-20170182173-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2017-06-29 | — | — | US | disclosed |
| US-20170182173-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2017-06-29 | — | — | US | disclosed |
| US-9572892-B2 | Polymer conjugate for delivery of a bioactive agent | POLYACTIVA PTY LTD (AU) | 2017-02-21 | — | — | US | disclosed |
| US-9572892-B2 | Polymer conjugate for delivery of a bioactive agent | POLYACTIVA PTY LTD (AU) | 2017-02-21 | — | — | US | disclosed |
| US-20160000929-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2016-01-07 | — | — | US | disclosed |
| US-20160000929-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000929-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | PTGIS, PTGIR, PGF | CHRM2 2424/4885CHRM4 2336/4885CHRM5 2660/4885 |
| US-20170216308-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | PTGIS, PTGIR, PGF | CHRM2 2271/4885CHRM4 2292/4885CHRM5 2289/4885 |
| US-20170182173-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | PTGIS, PTGIR, PGF | CHRM2 4153/4885CHRM4 3863/4885CHRM5 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.